Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a single-center, retrospective cohort study. The purpose is to evaluate different perioperative treatment options on the efficacy and survival prognosis of locally advanced GC/GEJC, clarify whether the tumor regression grade can influence survival of patients using neoadjuvant therapy. Moreover, we aim to explore the clinical and pathological characteristics that will affect the long-term survival benefit of patients who underwent perioperative treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| chemotherapy | patients who only used chemotherapy during neoadjuvant treatment |
| |
| immunochemotherapy | patients who used immunotherapy combined with chemotherapy during neoadjuvant treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chemo only | Procedure | Patients who only used chemotherapy during neodajuvant treatment period |
|
| Measure | Description | Time Frame |
|---|---|---|
| OS | overall survival | From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented death from any cause, assessed up to 100 months. |
| Measure | Description | Time Frame |
|---|---|---|
| EFS | event free survival | From the start date of cycle 1 (each cycle is 14 days or 21 days) neoadjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 100 months. |
| DFS |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
patients who had locally advanced GC/GEJC
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing | Beijing Municipality | 100021 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Immunochemotherapy | Procedure | Patients who used immunotherapy combined with chemotherapy during neodajuvant treatment period |
|
|
disease free survival
| From the start date of cycle 1 (each cycle is 14 days or 21 days) adjuvant therapy until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months. |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided